AIRR - ANZCA Institutional Research Repository
Skip navigation
Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCorcoran Tomas Ben_US
dc.contributor.authorMyles Paul Sen_US
dc.contributor.authorForbes Andrew Ben_US
dc.contributor.authorO'Loughlin Eden_US
dc.contributor.authorLeslie Kateen_US
dc.contributor.authorStory Daviden_US
dc.contributor.authorShort Timothy Gen_US
dc.contributor.authorChan Matthew TVen_US
dc.contributor.authorCoutts Paulineen_US
dc.contributor.authorSidhu Jaspretten_US
dc.contributor.authorCheng Allen Cen_US
dc.contributor.authorBach Leon Aen_US
dc.contributor.authorHo Kwok Men_US
dc.contributor.authorAustralian and New Zealand College of Anaesthetists Clinical Trials Network (ANZCA)en_US
dc.contributor.authorAustralian Society for Infectious Diseases (ASID) Clinical Research Networken_US
dc.identifier.citation2019 Sep 6;9(9):e030402.en_US
dc.description.abstractIntroduction: The intraoperative administration of dexamethasone for prophylaxis against postoperative nausea and vomiting is a common and recommended practice. The safety of the administration of this immunosuppressive agent at a time of significant immunological disruption has not been rigorously evaluated in terms of infective complications. Methods/analysis: This is a pragmatic, multicentre, randomised, controlled, non-inferiority trial. A total of 8880 patients undergoing elective major surgery will be enrolled. Participants will be randomly allocated to receive either dexamethasone 8 mg or placebo intravenously following the induction of anaesthesia in a 1:1 ratio, stratified by centre and diabetes status. Patient enrolment into the trial is ongoing. The primary outcome is surgical site infection at 30 days following surgery, defined according to the Centre for Disease Control criteria. Ethics/dissemination: The PADDI trial has been approved by the ethics committees of over 45 participating sites in Australia, New Zealand, Hong Kong, South Africa and the Netherlands. The trial has been endorsed by the Australia and New Zealand College of Anaesthetists Clinical Trials Network and the Australian Society for Infectious Diseases Clinical Research Network. Participant recruitment began in March 2016 and is expected to be complete in mid-2019. Publication of the results of the PADDI trial is anticipated to occur in early 2020. Trial registration number: ACTRN12614001226695.en_US
dc.subjectPostoperative Nausea and Vomitingen_US
dc.subjectSurgical Wound Infectionen_US
dc.titleThe perioperative administration of dexamethasone and infection (PADDI) trial protocol: rationale and design of a pragmatic multicentre non-inferiority studyen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMJ Openen_US
dc.type.studyortrialCase Control Studiesen_US
dc.contributor.anzcaaddAustralian Society for Infectious Diseases (ASID) Clinical Research Networken_US
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
Appears in Collections:Scholarly and Clinical
Show simple item record

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.